We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-5.68%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.44B
AUM Growth
+$573M
Cap. Flow
-$7.94M
Cap. Flow %
-0.55%
Top 10 Hldgs %
79.03%
Holding
50
New
2
Increased
4
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$8.82M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$8.28M
3
ASLN
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
+$7.68M
4
FULC icon
Fulcrum Therapeutics
FULC
+$4.93M
5
ZLAB icon
Zai Lab
ZLAB
+$2.99M

Top Sells

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$27.3M
2
VERA icon
Vera Therapeutics
VERA
+$7.75M
3
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$5.18M
4
MRUS
Merus
MRUS
+$1.48M
5
CMPX icon
Compass Therapeutics
CMPX
+$6.31K

Sector Composition

Rank Sector Weight
1 Healthcare 99.27%
2 Materials 0.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SERA icon
26
Sera Prognostics
SERA
$78.3M
$7.11M 0.49%
1,856,011
– –
KALV
27
DELISTED
KalVista Pharmaceuticals
KALV
$6.73M 0.47%
856,008
– –
DYN icon
28
Dyne Therapeutics
DYN
$4.89B
$6.65M 0.46%
577,642
– –
MRUS
29
DELISTED
Merus
MRUS
$6.51M 0.45%
353,600
-84,990
-19% -$1.48M
WHWK
30
Whitehawk Therapeutics
WHWK
$201M
$6.46M 0.45%
509,572
– –
OLMA icon
31
Olema Pharmaceuticals
OLMA
$1.01B
$5.86M 0.41%
1,689,515
– –
IOBT
32
DELISTED
IO Biotech
IOBT
$5.65M 0.39%
3,015,545
– –
BOLT icon
33
Bolt Biotherapeutics
BOLT
$7.59M
$5.38M 0.37%
193,565
– –
DBVT
34
DBV Technologies
DBVT
$843M
$4.58M 0.32%
270,888
– –
IMPL
35
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$4.04M 0.28%
2,884,789
– –
IOVA icon
36
Iovance Biotherapeutics
IOVA
$1.94B
$4M 0.28%
655,057
– –
ARWR icon
37
Arrowhead Research
ARWR
$12.2B
$3.49M 0.24%
137,411
– –
ALGS icon
38
Aligos Therapeutics
ALGS
$29.3M
$3.1M 0.22%
141,881
– –
GRCL
39
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$2.72M 0.19%
1,463,983
+502,625
+52% +$1.05M
BCAB icon
40
BioAtla
BCAB
$5.53M
$1.71M 0.12%
12,744
– –
ASLN
41
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$1.64M 0.11%
355,114
+284,091
+400% +$7.68M
CDXS icon
42
Codexis
CDXS
$156M
$1.61M 0.11%
388,144
– –
FULC icon
43
Fulcrum Therapeutics
FULC
$288M
$1.57M 0.11%
+550,000
New +$4.93M
IMUX icon
44
Immunic
IMUX
$191M
$942K 0.07%
63,218
– –
RZLT icon
45
Rezolute
RZLT
$451M
$940K 0.07%
489,473
– –
UTRS
46
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
$486K 0.03%
110,783
– –
QTTB icon
47
Q32 Bio
QTTB
$490M
$381K 0.03%
20,559
– –
DTIL icon
48
Precision BioSciences
DTIL
$193M
$106K 0.01%
4,675
– –
VERA icon
49
Vera Therapeutics
VERA
$2.18B
– –
-400,666
Closed -$7.75M
CINC
50
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
– –
-421,635
Closed -$5.18M
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.06% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return
CS
Central Securities New York $1.21B AUM 19.91% 1-Year Est. Return

Vivo Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Vivo Capital held 50 positions worth $1.44B, up 66% from $869M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Vivo Capital's Q1 2023 filing shows 2 new, 4 increased, 3 reduced and 2 closed positions. Its largest new stake was Arcellx: 290,713 shares worth $8.96M. The largest sale was Ventyx Biosciences, an estimated $27.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Materials.

  • Vivo Capital's largest Q1 2023 buy was Arcellx: 290,713 shares worth $8.96M.
  • Vivo Capital added most to Avadel Pharmaceuticals in Q1 2023, an estimated $8.28M increase.
  • Vivo Capital's biggest Q1 2023 reduction was Ventyx Biosciences, cutting an estimated $27.3M.
  • Vivo Capital fully exited Vera Therapeutics in Q1 2023, selling an estimated $7.75M.
  • Vivo Capital's ten largest holdings make up 79% of its $1.44B portfolio in Q1 2023.
  • Vivo Capital opened 2 new positions and closed 2 in Q1 2023.
  • Vivo Capital's portfolio value rose 66% quarter-over-quarter to $1.44B.

Based on Vivo Capital's 13F filing for Q1 2023, filed 15 May 2023.